Related Experiment Video
Updated: Mar 24, 2026
07:11
Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
Published on: May 23, 2025
1.1K
Modafinil improves monocrotaline-induced pulmonary hypertension rat model
Hyeryon Lee1, Kwan Chang Kim2, Min-Sun Cho3
1Department of Pediatrics, Ewha Womans University School of Medicine, Seoul, Republic of Korea.
Pediatric Research
|March 10, 2016
Summary
Modafinil effectively treats pulmonary arterial hypertension (PAH) by promoting vasodilation and reducing pulmonary artery wall thickness. This study demonstrates modafinil
Area of Science:
- Cardiovascular Research
- Pharmacology
- Pulmonary Medicine
Background:
- Pulmonary arterial hypertension (PAH) is characterized by progressive pulmonary vasoconstriction.
- Modafinil exhibits vasodilatory properties and can block the KCa3.1 channel, increasing cyclic adenosine monophosphate (cAMP) levels.
Purpose of the Study:
- To investigate the therapeutic effects of modafinil in a rat model of monocrotaline (MCT)-induced PAH.
Main Methods:
- Rats were divided into control, MCT-induced PAH, and MCT-induced PAH treated with modafinil groups.
- Hemodynamic parameters, cardiac structure, and pulmonary vascular remodeling were assessed.
Main Results:
- Modafinil treatment reduced right ventricular pressure and improved right ventricular hypertrophy.
- Pulmonary artery remodeling, including medial wall thickness and vessel count, was ameliorated by modafinil.
- Modafinil downregulated protein expression of endothelin-1 (ET-1), endothelin receptor A (ERA), and KCa3.1, suppressing pulmonary artery smooth muscle cell proliferation via cAMP.
Conclusions:
- Modafinil demonstrates efficacy in improving PAH by inducing vasorelaxation and reducing medial thickening.
- These improvements are mediated through the downregulation of ET-1, ERA, and KCa3.1 signaling pathways.
